Research programme: melanocortin 1 receptor agonist peptides - Klotho Neurosciences
Latest Information Update: 24 Sep 2024
At a glance
- Originator Unknown
- Developer Klotho Neurosciences
- Class Peptides; Skin disorder therapies
- Mechanism of Action Melanocortin type 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Skin disorders
Most Recent Events
- 17 Sep 2024 ANEW MEDICAL is now called Klotho Neurosciences
- 09 Aug 2024 ANEW MEDICAL enters into a worldwide licensing agreement with Teleost Biopharmaceuticals and the University of Arizona for the development of melanocortin receptor agonist peptides, prior to August 2024
- 14 Feb 2023 ANEW MEDICAL in-licenses technology from Teleost Biopharmaceuticals